Streptococcus suis cDNA and recombinant antigen

Streptococcus suis is a species of Gram-positive, facultatively anaerobic, coccus-shaped bacteria that is part of the normal flora of pigs. It can also cause serious illnesses in humans, including sepsis, meningitis, and endocarditis. Streptococcus suis produces various surface antigens, including one called the surface antigen. This antigen plays a crucial role in the bacterium’s ability to attach to host tissues and evade the host immune system.

Interestingly, S. suis also produces a negative regulator called Par, which downregulates the expression of surface antigens. This allows the bacterium to avoid detection by the host immune system and facilitate bacterial colonization.

Understanding the mechanisms by which S. suis regulates surface antigen expression and evades the host immune system is crucial for developing effective treatments and vaccines against this pathogen. By targeting these antigens and their regulation, researchers can develop new strategies for preventing and treating S. suis infections.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.

Streptococcus suis cDNA and recombinant antigens may be used in a variety of applications. One application is in the development of vaccines against S. suis. The cDNA can be used to identify and clone genes that encode proteins that are involved in the virulence of the bacteria. Once these proteins have been identified, the cDNA can be used to create recombinant antigens that can be used to create a vaccine. Recombinant antigens can also be used in diagnostic tests to detect the presence of S. suis in an animal or human. Additionally, the cDNA and antigens can be used to identify new targets for future drug development and to study the genetics and evolution of the pathogen.